Fig. 5

Heatmap, PCA and PLS-ROG analysis. a Heat map analysis of all samples showed that the kidney metabolic profile was altered mainly by I/R injury rather than XOR inhibitor interventions. b PCA results coincided with heat map data in that PC1 and PC2 clearly distinguished metabolic alterations by hemodynamic changes; each of the stationary, ischemic, and reperfused states formed a separate cluster. Partial least squares with rank order of groups (PLS-ROG) analysis of samples in the stationary, ischemic and reperfused states. c Based on PLS-ROG analysis in the stationary state, febuxostat-treated (Feb-S) and topiroxostat-treated (Top-S) samples show rather similar metabolic alterations but different from those in the two other groups. Vehicle-treated samples (Veh-S) had a metabolic profile distinguishable from those of XOR inhibitor-treated groups (Feb-S, Top-S, and Allo-S) by factor loadings for PLS1. Allopurinol-treated samples (Allo-S) were distinguishable from the other groups by factor loadings for PLS3. d In the ischemic state, vehicle-treated samples (Veh-I) had a metabolic profile distinguishable from those of XOR-inhibitor-treated groups (Feb-I, Top-I, and Allo-I) by factor loadings for PLS1. e In the reperfused state, vehicle-treated samples (Veh-R) had a metabolic profile distinguishable from those of XOR-inhibitor treated groups (Feb-R, Top-R, and Allo-R) by factor loadings for PLS2. Allopurinol-treated samples (Allo-R) were distinguishable from the other groups by factor loadings for PLS3